AstraZeneca spinout Entasis files for $86M IPO to fund antibiotic phase 3

AstraZeneca spinout Entasis files for $86M IPO to fund antibiotic phase 3

Source: 
Fierce Biotech
snippet: 

Entasis Therapeutics has filed to raise up to $86 million through an IPO. The AstraZeneca spinout is seeking the money to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams.